Paul G. Richardson, MD

Articles

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

June 23rd 2020

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

June 4th 2020

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

June 2nd 2020

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory Myeloma

March 3rd 2020

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Richardson on Preliminary Data With Belantamab Mafodotin in Multiple Myeloma

December 12th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the preliminary data that has been reported with belantamab mafodotin (GSK2857916) in multiple myeloma.

Dr. Richardson on Results of the HORIZON Trial in Relapsed/Refractory Multiple Myeloma

September 16th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Richardson Discusses New Directions in Multiple Myeloma

July 24th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma.

Innovation Fuels Survival Gains in Multiple Myeloma

June 12th 2019

While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.

Dr. Richardson on Isatuximab Triplet Regimen in Relapsed/Refractory Myeloma

June 4th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Richardson on Immunotherapy Advances in Relapsed/Refractory Myeloma

May 22nd 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses advances made with immunotherapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Richardson on Treatment Approaches Targeting Mutational Burden in Myeloma

April 23rd 2019

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School, discusses treatment approaches targeting mutational burden in multiple myeloma.